argenx SE
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
210 / 1361
Position in country
112 / 223
Net income margin, %
-23.4
-180
EBITDA margin, %
-14.7
-168.2
Debt to Equity, %
0.4
3.2
Intangible assets and goodwill, %
2.7
0.2
Revenue CAGR 3Y, %
209.8
12.5
Revenue Y, % chg
198.5
0
P/BV
5.4
1.8
P/S
18.2
10.3
EV/S
15.7
7.5
EV/EBITDA
-62.2
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
26.4
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
CSL Ltd
00%
-
NewAmsterdam Pharma Company NV
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
argenx SE
00%
-
Merus NV
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
AbbVie Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Netherlands
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
22417.4
Ticker
ARGX.OQ
ISIN
US04016X1019
IPO date
2014-07-10
Availability on Russian exchanges
No
Reporting for
2024-03-21
Date fact. publication of reports
2023-12-31
Company Description
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: